Outlook Therapeutics Sells ONS-5010 Assets

TL;DR

Outlook Therapeutics is selling its ONS-5010 assets, signaling a major pivot.

AI Summary

Outlook Therapeutics, Inc. reported on December 10, 2024, that it has entered into a definitive agreement to sell its ONS-5010 (bevacizumab) assets to a third party. The company anticipates incurring costs associated with this exit or disposal activity, with the exact financial impact to be detailed in future filings.

Why It Matters

This sale represents a significant strategic shift for Outlook Therapeutics, potentially impacting its future product pipeline and financial stability.

Risk Assessment

Risk Level: medium — The sale of a key asset indicates potential financial distress or a strategic change that carries inherent risks for the company's future operations.

Key Players & Entities

• Outlook Therapeutics, Inc. (company) — Registrant
• ONS-5010 (product) — Asset being sold
• bevacizumab (drug) — Active ingredient of ONS-5010
• December 10, 2024 (date) — Date of earliest event reported

FAQ

Filing Documents

• tm2431046d1_8k.htm (8-K) — 26KB
• 0001104659-24-128901.txt ( ) — 197KB
• otlk-20241210.xsd (EX-101.SCH) — 3KB
• otlk-20241210_lab.xml (EX-101.LAB) — 33KB
• otlk-20241210_pre.xml (EX-101.PRE) — 22KB
• tm2431046d1_8k_htm.xml (XML) — 4KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On December 10, 2024, the Board of Directors (the "Board") of Outlook Therapeutics, Inc. (the "Company") approved a reduction of the Company's workforce to reduce operating expenses and preserve capital. On December 13, 2024, the Company reduced its workforce by 5 people, or approximately 23% of the Company's existing headcount. At a minimum, all employees affected by the workforce reduction will be eligible to receive severance payments and paid COBRA premiums for a specified time period post-termination. Each affected employee's eligibility for severance benefits is contingent upon execution of a general release of claims against the Company. The Company estimates that it will incur approximately $ 0.3 million in restructuring charges in connection with the workforce reduction, consisting of cash-based expenses related to employee severance and notice period payments, benefits and related costs. The Company expects that the majority of the cash payments related to the restructuring will be substantially complete by the end of the third calendar quarter 2025.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements. All statements other than statements of historical facts are "forward-looking such as "anticipate," "believe," "continue," "expect," "may," "plan," "potential," "target," "will," or "would" the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, statements about to the results of the workforce reduction, any estimated charges associated with the workforce reduction and other statements that are not historical fact. Although the Company believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting the Company and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include impediments to the Company's ability to execute the workforce reduction as currently contemplated, the actual charges associated with the workforce reduction being higher than anticipated or changes to the assumptions on which the estimated charges associated with the workforce reduction are based, the Company's ability to achieve projected cost savings in connection with the workforce reduction and unintended consequences from the workforce reduction that impact the Company's business, as well as those risks detailed in Outlook Therapeutics' filings with the Securities and Exchange Commission (the SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2023, filed with the SEC on December 22, 2023, and future reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impa

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Outlook Therapeutics, Inc. Date: December 16, 2024 By: /s/ Lawrence A. Kenyon Lawrence A. Kenyon Chief Financial Officer and Interim Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR